AngioDynamics to Hold Fiscal First Quarter Earnings Conference Call on October 2, 2008
Eamonn P. Hobbs, president and chief executive officer, and Joseph Gersuk, executive vice president and CFO, will host an investment community conference call beginning at 4:30 p.m. Eastern time on October 2 to discuss these results and to answer questions.
To participate in the live call by telephone, please dial (800) 218-0204 from the U.S., or for international callers, please dial +1 (303) 262-2053.
Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of AngioDynamics' website at http://investor.angiodynamics.com. To listen to the live call, please go to the website 15 minutes prior to its start to register, download, and install the necessary audio software.
A replay will be available on the website. A telephone replay will be available from 6:30 p.m. Eastern time on October 2, 2008 through 11:59 p.m. Eastern time on October 9 by dialing (800) 405-2236 (domestic) or +1 (303) 590-3000 (international) and entering the passcode: 11119718#.
About AngioDynamics
AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease. The Company's diverse product line includes market-leading radiofrequency ablation and irreversible electroporation resection systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.angiodynamics.com.
CONTACT: AngioDynamics, Inc.
D. Joseph Gersuk, CFO, 800-772-6446 ext. 1608
jgersuk@AngioDynamics.com
or
EVC Group, Inc.
Doug Sherk, 415-896-6820 (Investor Relations)
dsherk@evcgroup.com
Jenifer Kirtland, 415-896-6820 (Investor Relations)
jkirtland@evcgroup.com
Chris Gale, 646-201-5431 (Media)
cgale@evcgroup.com
SOURCE: AngioDynamics, Inc.